Pentagalloyl Glucose

Pentagalloyl Glucose

SCHEMBL675693

O=C(OC[C@H]1OC(OC(=O)c2cc(O)c(O)c(O)c2)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.86
MAPK1 P28482 2/20 0.86
TMPRSS2 O15393 1/20 0.86
PDE5A O76074 1/20 0.86
CA1 P00915 1/20 0.86
CA2 P00918 1/20 0.86
HMGCR P04035 1/20 0.86
CYP1A2 P05177 1/20 0.86
LCK P06239 1/20 0.86
FYN P06241 1/20 0.86
HSPD1 P10809 1/20 0.86
CYP2C9 P11712 1/20 0.86
CA6 P23280 1/20 0.86
TBXAS1 P24557 1/20 0.86
MAPK3 P27361 1/20 0.86
HSPE1 P61604 1/20 0.86
MAPK14 Q16539 1/20 0.86
TST Q16762 1/20 0.86
SLCO1B3 Q9NPD5 1/20 0.86
L3MBTL1 Q9Y468 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pentagalloyl Glucose SCHEMBL17019593 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1
Pentagalloyl Glucose SCHEMBL3147610 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1
Pentagalloyl Glucose SCHEMBL13286947 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1
Pentagalloyl Glucose SCHEMBL12129801 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1
Pentagalloyl Glucose SCHEMBL2787135 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1
Pentagalloyl Glucose SCHEMBL23484369 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1
Pentagalloyl Glucose SCHEMBL14257930 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1
Pentagalloyl Glucose SCHEMBL640108 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1
Pentagalloyl Glucose SCHEMBL14266926 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1
Pentagalloyl Glucose SCHEMBL2789358 1.00 USP2 (0.86) USP2MAPK1TMPRSS2PDE5ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110448563-A Application of 1,2,3,4, the 6- Penta-O-galloyl-D-glucopyranose in preparation prevention and treatment osteoporosis drug UNIV NANJING CHINESE MEDICINE 2019-11-15 CN claimed
CN-110384827-A The processing method of biological tissue 百多力股份公司 2019-10-29 CN claimed
CN-110272459-A Two kinds of noval chemical compounds and its antioxidant activity position in root of Paeonia sinjiangensis 中国药科大学 2019-09-24 CN claimed
CN-109632991-A A method of utilizing HPLC characteristic spectrum detection and identification Radix Paeoniae Alba and stir-baked RADIX PAEONIAE ALBA with vino 广东方制药有限公司 2019-04-16 CN claimed
CN-109490437-A The fingerprint atlas detection method of Radix Paeoniae Alba 南京海昌中药集团有限公司 2019-03-19 CN claimed
CN-106699819-B The preparation method of Penta-O-galloyl-D-glucopyranose chemical reference substance 泸州飞翔医药科技有限公司 2019-03-05 CN claimed
CN-109125333-A Penta-O-galloyl-D-glucopyranose and 5 FU 5 fluorouracil are combined inhibiting effect and its application to HepG2 cancer cell invasion phenotype 内蒙古大学 2019-01-04 CN claimed
CN-108760948-A A kind of preparation method of 1,2,3,4,6-O- Penta-O-galloyl-D-glucopyranoses standard sample 中国林业科学研究院林产化学工业研究所 2018-11-06 CN claimed
CN-108635588-A The noble metal nano particles and its preparation method and application of Medicine small molecule modification 国家纳米科学中心 2018-10-12 CN claimed
CN-108246214-A The method that one step absorption method prepares polypeptide microcapsule 温州生物材料与工程研究所 2018-07-06 CN claimed
US-20120321566-A1 INHIBITION OF BIOFILM FORMATION BY 1,2,3,4,6-PENTA-O-GALLOYL-D-GLUCOPYRANOSE CHANG GUNG UNIVERSITY (TW) 2012-12-20 US claimed
EP-2462944-A2 Methods and compositions for prevention and treatment of diabetic and aged skin HealOr Ltd. (IL) 2012-06-13 EP claimed
EP-2452691-A2 Methods and compositions for prevention of diabetic and aged skin HealOr Ltd. (IL) 2012-05-16 EP claimed
EP-2452686-A2 Methods and compositions for prevention and treatment of diabetic and aged skin HealOr Ltd. (IL) 2012-05-16 EP claimed
EP-2452687-A2 Methods and compositions for prevention and treatment of diabetic and aged skin HealOr Ltd. (IL) 2012-05-16 EP claimed
US-20090203150-A1 METHODS AND SYSTEMS FOR IDENTIFYING INSULIN MIMETICS OHIO UNIVERSITY (US) 2009-08-13 US claimed
EP-1940440-A2 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF DIABETIC AND AGED SKIN Healor Ltd. (IL) 2008-07-09 EP claimed
WO-2007026356-A2 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF DIABETIC AND AGED SKIN HEALOR LTD. (IL) 2007-03-08 WO claimed
WO-2007028126-A2 METHODS AND SYSTEMS FOR IDENTIFYING INSULIN MIMETICS OHIO UNIVERSITY (US) 2007-03-08 WO claimed
US-20030078212-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME GUILFORD PHARMACEUTICALS INC. 2003-04-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120321566-A1 INHIBITION OF BIOFILM FORMATION BY 1,2,3,4,6-PENTA-O-GALLOYL-D-GLUCOPYRANOSE PGLS, UGGT1, FUT6 USP2 2164/4885MAPK1 847/4885TMPRSS2 2552/4885
US-20030078212-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME PARP10, PARG, DERA USP2 4675/4885MAPK1 2656/4885TMPRSS2 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.